HuGEMM™ Human PD-1 Knock-In Model

Evaluate anti-PD-1 immuno-oncology agents in vivo with humanized drug target mouse models

dna-mouse.png

The HuGEMM PD-1 knock-in mouse provides a translational model for testing your human-specific anti-PD-1 agents. This model has humanized PD-1 receptors and a functional mouse immune system.

The PD-1 model was developed by knocking-in human exon 2 to replace its mouse counterpart. This allows the in vivo efficacy evaluation of human therapeutic antibodies which recognize the humanized receptor.

  • Evaluate your human specific biological therapies in vivo when no mouse ortholog is available

  • Efficiently study a range of targets for human immunotherapies

  • Save study resources by using a cost-effective alternative to more complex fully humanized models

Model Characterization Data

Figure 1: The chimeric h/mPD-1 protein binds in vitro to both mouse and human PD-L1 as efficiently as the human PD-1 receptor (upper panel). The chimeric protein is also recognized by anti-human PD-1 antibodies (lower panel), which disrupts the PD-1/PD-L1 interaction

Figure 2: Validation of HuGEMM PD-1 with an analog of Opdivo®. Dose dependent inhibition of subcutaneous MC38 tumor growth is observed following treatment with the anti-hPD-1 antibody.

Discuss your Humanized Target Project